Coronavirus information from UCLA and UCLA Health.

Capacity Bio is developing the most comprehensive and advanced mitophagy therapeutics and development platform for the purpose of restoring mitochondria quality control in disease.

Market:

Their lead focus is neurodegeneration and muscular disorders, including Parkinson's, ALS, and DMD which targets multibillion opportunities.

Technology:

Capacity Bio has a unique set of drugs that improve mitochondrial quality control by targeting receptors on the cell surface.

Advantages:

  • Engage target quickly and efficiently
  • No need to enter cell or mitochondria
  • Safe and effective

Development Stage:

  • Pre-Clinical

Patents Issued:

  • Coming Soon

Select Publications:

  • Coming Soon

Contact:

Email: awang@capacitybio.com
Phone: 310-880-6414
Website: www.capacitybio.com
LinkedIn